We use cookies on our website. Some are necessary for the operation of the website. You can also allow cookies for statistical purposes. You can adjust the data protection settings or agree to all cookies directly.
Data Protection Declaration
Imprint
Developing innovative treatment methods for the treatment of infections with influenza viruses
Project
Project code: 2813200506
Contract period: 15.03.2007
- 14.03.2010
Budget: 583,035 Euro
Purpose of research: Experimental development
Within the present project supported by the BMELV proteasome inhibitors (PI) were tested as a new strategy for treatment of Influenza A Virus (IAV)-infections. The presented results indicate that PI can interfere with the course of infection of both, human and highly pathogenic avian IAV strains. In vitro studies show that PI can modulate various signalling pathways and transcription factors which are known to play an important role in antiviral immunity. In this context an enhanced transcription of proteins with known antiviral activity, such as MxA, was found following treatment with PI (Dudek et al. J Virol. 2010; 84(18):9439). Furthermore, PI were tested for antiviral activity in mouse models. These studies show an effect of pre-treatment with PI in IAV-infected mice. Animals pre-treated with PI showed a significant survival advantage compared to mock treated animals. In vivo studies using highly pathogenic avian IAV strains showed that pre-treatment with PI leads to a significant decrease in the IAV-induced cytokine release (cytokine storm) (Haasbach et al. Antiviral Res. 2011; 91(3):304).
Section overview
Subjects
- Animal health
